{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:49:35Z","timestamp":1790480975478,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s40262-019-00829-2","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T07:46:13Z","timestamp":1572507973000},"page":"575-589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Exposure\u2013Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis"],"prefix":"10.1007","volume":"59","clinical-trial-number":[{"clinical-trial-number":"nct03000075","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03022045","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02672852","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02684357","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02684370","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02694523","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02054481","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ahmed A.","family":"Suleiman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajneet K.","family":"Oberoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4937-2775","authenticated-orcid":false,"given":"Ahmed A.","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"key":"829_CR1","unstructured":"International Federation of Psoriasis Associations (IFPA) World Psoriasis Day. About psoriasis. http:\/\/www.worldpsoriasisday.com\/web\/page.aspx?refid=114. Accessed Feb 2014."},{"key":"829_CR2","unstructured":"Kubota K, Sato M, Ohaba N, et al. Potential usage of National Receipt database: epidemiology study of psoriasis. Japanese Society of Pharmacoepidemiology, 16\u201317 Nov 2013; Tokyo. p. 39."},{"key":"829_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12016-018-8668-1","volume":"54","author":"C Conrad","year":"2018","unstructured":"Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies. Clin Rev Allergy Immunol. 2018;54:102\u201313.","journal-title":"Clin Rev Allergy Immunol"},{"key":"829_CR4","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1111\/jdv.14949","volume":"32","author":"KM Hoegler","year":"2018","unstructured":"Hoegler KM, John AM, Handler MZ, Schwartz RA. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018;32:1645\u201351.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"829_CR5","first-page":"93","volume":"6","author":"RK Singh","year":"2016","unstructured":"Singh RK, Lee KM, Ucmak D, Brodsky M, Atanelov Z, Farahnik B, et al. Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:93\u2013104.","journal-title":"Psoriasis (Auckl)"},{"key":"829_CR6","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.2147\/DDDT.S167149","volume":"12","author":"IM Haugh","year":"2018","unstructured":"Haugh IM, Preston AK, Kivelevitch DN, Menter AM. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. Drug Des Dev Ther. 2018;12:3879\u201383.","journal-title":"Drug Des Dev Ther"},{"key":"829_CR7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s40257-018-0406-1","volume":"19","author":"ZT Al-Salama","year":"2018","unstructured":"Al-Salama ZT, Scott LJ. Guselkumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol. 2018;19:907\u201318.","journal-title":"Am J Clin Dermatol"},{"key":"829_CR8","unstructured":"Stelara (ustekinumab) [US prescribing information]. Horsham: Janssen Biotech Inc.; 2018."},{"key":"829_CR9","unstructured":"Tremfya (guselkumab) [US prescribing information]. Horsham: Janssen Biotech Inc.; 2017."},{"key":"829_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaci D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390:276\u201388.","journal-title":"Lancet"},{"key":"829_CR11","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1080\/19420862.2015.1032491","volume":"7","author":"S Singh","year":"2015","unstructured":"Singh S, Kroe-Barrett RR, Canada KA, Zhu X, Sepulveda E, Wu H, et al. Selective targeting of the IL23 pathway: generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs. 2015;7:778\u201391.","journal-title":"MAbs"},{"key":"829_CR12","unstructured":"Skyrizi\u2122 (risankizumab injection) [US prescribing information]. North Chicago: AbbVie Inc; 2019."},{"key":"829_CR13","unstructured":"Skyrizi 75\u00a0mg solution for injection in pre-filled syringe [summary of product characteristics]. Ludwigshafen: AbbVie Deutschland GmbH and Co. KG; 2019."},{"key":"829_CR14","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392:650\u201361.","journal-title":"Lancet"},{"key":"829_CR15","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Thaci D, Crowley JJ, Ryan C, Krueger JG, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394:576\u201386.","journal-title":"Lancet"},{"key":"829_CR16","first-page":"e248","volume":"177","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Gooderham M, Langley RG, Leonardi C, Lacour JP, et al. Efficacy and safety of risankizumab, an interleukin-23 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis: 16-week results from the phase III IMMhance trial. Br J Dermatol. 2017;177:e248.","journal-title":"Br J Dermatol"},{"issue":"8","key":"829_CR17","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/1346-8138.14941","volume":"46","author":"M Ohtsuki","year":"2019","unstructured":"Ohtsuki M, Fujita H, Watanabe M, Suzaki K, Flack M, Huang X, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2\/3 trial. J Dermatol. 2019;46(8):686\u201394.","journal-title":"J Dermatol"},{"key":"829_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1594","author":"A Khatri","year":"2019","unstructured":"Khatri A, Suleiman A, Polepally A, Othman A. Exposure\u2013response relationships for efficacy and safety of risankizumab in phase 2 and 3 trials in psoriasis patients. Clin Pharmacol Ther. 2019. https:\/\/doi.org\/10.1002\/cpt.1594.","journal-title":"Clin Pharmacol Ther"},{"key":"829_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1473","author":"A Khatri","year":"2019","unstructured":"Khatri A, Eckert D, Oberoi R, Suleiman A, Pang Y, Cheng L, et al. Pharmacokinetics of risankizumab in Asian healthy subjects and patients with moderate-to-severe plaque psoriasis, generalized pustular psoriasis, and erythrodermic psoriasis. J Clin Pharmacol. 2019. https:\/\/doi.org\/10.1002\/jcph.1473.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"829_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40262-018-0704-z","volume":"58","author":"AA Suleiman","year":"2019","unstructured":"Suleiman AA, Khatri A, Minocha M, Othman AA. Population pharmacokinetics of the interleukin-23 inhibitor risankizumab in subjects with psoriasis and Crohn\u2019s disease: analyses of phase I and II trials. Clin Pharmacokinet. 2019;58(3):375\u201387.","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00829-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-019-00829-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00829-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:28:59Z","timestamp":1628616539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-019-00829-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,31]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["829"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00829-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,31]]},"assertion":[{"value":"31 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was sponsored by Boehringer Ingelheim and AbbVie. Boehringer Ingelheim contributed to the study designs and data collection and AbbVie contributed to the analysis and interpretation of data, and the writing, review, and approval of the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ahmed Suleiman is an AbbVie employee. Ahmed A. Othman, Amit Khatri, and Rajneet K. Oberoi are former employees of AbbVie. All authors may hold AbbVie stock or stock options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g., protocols and Clinical Study Reports), provided the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. These clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan and execution of a Data Sharing Agreement. Data requests can be submitted at any time and the data will be accessible for 12\u00a0months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}}]}}